WO1994011103A1 - Magnetic solid phase supports - Google Patents

Magnetic solid phase supports Download PDF

Info

Publication number
WO1994011103A1
WO1994011103A1 PCT/GB1993/002289 GB9302289W WO9411103A1 WO 1994011103 A1 WO1994011103 A1 WO 1994011103A1 GB 9302289 W GB9302289 W GB 9302289W WO 9411103 A1 WO9411103 A1 WO 9411103A1
Authority
WO
WIPO (PCT)
Prior art keywords
msps
magnetisable
particles according
particles
magnetisable particles
Prior art date
Application number
PCT/GB1993/002289
Other languages
French (fr)
Inventor
Ian James Bruce
Martin John Davies
Geoffrey Eric Scopes
Diane Elizabeth Smethurst
Original Assignee
Williams, John, Francis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Williams, John, Francis filed Critical Williams, John, Francis
Priority to EP93924712A priority Critical patent/EP0621802A1/en
Priority to AU54273/94A priority patent/AU5427394A/en
Publication of WO1994011103A1 publication Critical patent/WO1994011103A1/en

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/281Sorbents specially adapted for preparative, analytical or investigative chromatography
    • B01J20/291Gel sorbents
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/10Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/18Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
    • B01D15/1807Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using counter-currents, e.g. fluidised beds
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/26Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804Affinity chromatography
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/28Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
    • B01J20/28002Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their physical properties
    • B01J20/28009Magnetic properties
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30Processes for preparing, regenerating, or reactivating
    • B01J20/3007Moulding, shaping or extruding
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30Processes for preparing, regenerating, or reactivating
    • B01J20/32Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3202Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
    • B01J20/3206Organic carriers, supports or substrates
    • B01J20/3208Polymeric carriers, supports or substrates
    • B01J20/3212Polymeric carriers, supports or substrates consisting of a polymer obtained by reactions otherwise than involving only carbon to carbon unsaturated bonds
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30Processes for preparing, regenerating, or reactivating
    • B01J20/32Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3231Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
    • B01J20/3242Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
    • B01J20/3244Non-macromolecular compounds
    • B01J20/3246Non-macromolecular compounds having a well defined chemical structure
    • B01J20/3248Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30Processes for preparing, regenerating, or reactivating
    • B01J20/32Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3231Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
    • B01J20/3242Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
    • B01J20/3244Non-macromolecular compounds
    • B01J20/3246Non-macromolecular compounds having a well defined chemical structure
    • B01J20/3248Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such
    • B01J20/3251Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such comprising at least two different types of heteroatoms selected from nitrogen, oxygen or sulphur
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30Processes for preparing, regenerating, or reactivating
    • B01J20/32Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3231Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
    • B01J20/3242Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
    • B01J20/3244Non-macromolecular compounds
    • B01J20/3246Non-macromolecular compounds having a well defined chemical structure
    • B01J20/3248Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such
    • B01J20/3255Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such comprising a cyclic structure containing at least one of the heteroatoms nitrogen, oxygen or sulfur, e.g. heterocyclic or heteroaromatic structures
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30Processes for preparing, regenerating, or reactivating
    • B01J20/32Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3291Characterised by the shape of the carrier, the coating or the obtained coated product
    • B01J20/3293Coatings on a core, the core being particle or fiber shaped, e.g. encapsulated particles, coated fibers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326Magnetic particles
    • G01N33/5434Magnetic particles using magnetic particle immunoreagent carriers which constitute new materials per se
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2220/00Aspects relating to sorbent materials
    • B01J2220/50Aspects relating to the use of sorbent or filter aid materials
    • B01J2220/54Sorbents specially adapted for analytical or investigative chromatography
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/12Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar
    • G01N2400/32Galactans, e.g. agar, agarose, agaropectin, carrageenan
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2446/00Magnetic particle immunoreagent carriers
    • G01N2446/20Magnetic particle immunoreagent carriers the magnetic material being present in the particle core
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2446/00Magnetic particle immunoreagent carriers
    • G01N2446/30Magnetic particle immunoreagent carriers the magnetic material being dispersed in the polymer composition before their conversion into particulate form
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2446/00Magnetic particle immunoreagent carriers
    • G01N2446/80Magnetic particle immunoreagent carriers characterised by the agent used to coat the magnetic particles, e.g. lipids
    • G01N2446/84Polymer coating, e.g. gelatin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2446/00Magnetic particle immunoreagent carriers
    • G01N2446/80Magnetic particle immunoreagent carriers characterised by the agent used to coat the magnetic particles, e.g. lipids
    • G01N2446/90Magnetic particle immunoreagent carriers characterised by the agent used to coat the magnetic particles, e.g. lipids characterised by small molecule linker used to couple immunoreagents to magnetic particles

Definitions

  • This invention relates to the isolation and purification of molecules of biological interest eg proteins, nucleic acids, and other biopolymers.
  • An affinity chromatography step is often the final or penultimate step. Ideally this step should be employed as early as possible in the process to maximise the yield of desired product and minimise the time required to generate it. Usually this is not feasible as the substance of interest (ligate) is present in a medium not readily amenable to conventional column affinity chromatography. Often the ligate may be present in a mixture of substances containing particulate and/or semi-solid or colloidal material such as cell debris and denatured cell components and/or in a mixture which is highly viscous.
  • the present invention is concerned with the development of relatively simple techniques for use with complex mixtures of high viscosity and/or those containing particulate matter and which are based on the use of magnetisable solid phase support (MSPS) materials.
  • MSPS magnetisable solid phase support
  • the present invention comprises magnetisable polymer based particles derivatised with ligands possessing direct-binding affinities for nucleic acids and other types of biomolecule, and the use of these particles for nucleic acid (and other biomolecular) purification and speciation, including double or single stranded nucleic acids, genomic DNA, plasmid DNA, and cellular RNA.
  • the direct binding of the ligand to the target molecule is important to achieve the benefits of this invention as contrasted with prior proposals based on indirect linking of the target molecules eg. through intercalating agents as described in EP 301,899 A.
  • the present invention comprises particulate support material having magnetic properties and bearing a ligand which binds to molecules of a specific type. From another aspect the present invention comprises a method of separating biomolecules of various types by binding such molecules to ligands which are selective therefore and which are attached to magnetisable particulate support materials. The invention is further apparent from the appended claims.
  • the magnetic susceptibility of MSPS materials in accordance with the present invention is a function of the weight and size of the particulate material and the quantity of paramagnetic material incorporated therein. This property may therefore be adjusted as desired in order to provide an appropriate selection parameter.
  • a product range of MSPS materials may be manufactured in order to cater for the wide range of separations encountered in both analytical and preparative procedures.
  • the MSPS materials in accordance with this invention are preferably gels and are conveniently in the form of beads. Such gels may be stabilised by crosslinking eg with epichlorohydrin, leading to greater particle stability especially at high temperatures.
  • Many polymers may be used for the purposes of this invention including cellulose, dextran, polyacrylamide and the synthetic material trisacryl.
  • One of the most preferred materials is agarose.
  • the positive benefits of this polymer are gel strength and biological inertness.
  • the abundance of hydroxyl groups possessed by the agarose matrix allows for easy covalent attachment of various ligands desirable for molecular biology applications and its non-covalent secondary structure also engenders structural stability, porosity and ease of shaping into spheres. Since many molecular biology methodologies are performed at temperatures above that at which agarose melts it would also be desirable to introduce thermal stability into the agarose solid phase support.
  • MSPS materials consist of at least two separate components a non-magnetisable component which may be chemically derivatised with suitable ligands and a magnetisable component or core.
  • Paramagnetic properties can be introduced into the solid phase support by addition of powdered paramagnetic iron oxide (Fe 3 0 4 ) to the agarose during the preparation of the MSPS, which leads to entrapment of the paramagnetic component within the solid phase matrix and gives the particles their magnetisability.
  • MSPS particles should be within a size range which allows the greatest particle surface area exposure to ligate, but at the same time allows the best particle magnetic sedimentation rate.
  • the magnetisable component should also have a high degree of magnetisable susceptibility to optimise magnetic sedimentation rates.
  • the ideal magnetisable component can be selected on the basis of the above equation, but in practice relatively few paramagnetic molecules have been used in MSPS. Iron oxide, barium ferrite and nickel oxide may be used.
  • MSPS construction since it possesses a high magnetic susceptibility, is readily available, inexpensive and non toxic.
  • a highly preferred system for our purposes entails iron oxide as the magnetisable component for
  • MSPS and agarose as the polymer matrix in which to embed it.
  • other natural and synthetic polymers may be used as MSPS matrix material including cellulose, alginate, dextran and perfluorocarbon based supports.
  • MSPS may be prepared either by encapsulation of the magnetisable component during the preparation of the particle, or by addition of the magnetisable component subsequent to particle formation.
  • the magnetisable component can be mixed in an aqueous suspension of cellulose or agarose and allowed to cure, the water is removed and the dried material ground to the size range required.
  • MSPS may be prepared by spraying or droplet formation and this leads to beaded particles.
  • MSPS may be prepared by addition of a suspension of sodium alginate and iron oxide dropped into a solution of calcium chloride. Droplet formation can be brought about through emulsification techniques and thee have been employed for the formation of spherical magnetisable dextran, albumin, acrylates, acrolein and polyglutaraldehyde. In this system an aqueous emulsion of the matrix polymer and magnetisable component is prepared. This is added to mineral oil and the two phase system stirred. A precipitate is formed of beaded particles.
  • the particle is coated with an aqueous solution of polyacrylamide containing ferric oxide.
  • the resulting particles tend to be large >250 ⁇ and very porous. However, they are amenable to activation via either the polysaccharide or polyacrylamide component.
  • agarose MSPS In one method we have used to prepare agarose MSPS an aqueous suspension is extruded into an immiscible organic phase.
  • a suspension of paramagnetic iron oxide, Fe 3 0 4 , (4% w/v) in molten agarose (2% w/v) was extruded into vegetable oil stirred with an overhead paddle stirrer using a specially adapted plastic syringe. The end of the syringe was sealed, then drilled with a small hole to allow the molten agarose/iron oxide mixture to be extruded into the oil phase.
  • the MSPS was collected, washed with water and sized by sieving, then checked under a light microscope set up for K ⁇ hler illumination for morphological homogeneity. The particles formed were highly bead like and uniformly spherical, a consequence of both the extrusion technique and the immiscibility of the oil and water.
  • the highly spherical nature of the particles produced is particularly desirable because it prevents local concentration change effects that might occur with particles whose surface is more heterogeneous. It is particularly important to maintain uniform ionic concentrations around the surface of a particle in order that local absorption and/or desorption does not occur and alter the bulk properties of the support.
  • MSPS When the MSPS was viewed under the light microscope, small yellow inclusions were observed incorporated within the agarose matrix which were believed to be vegetable oil retained in the matrix of the agarose during the preparation of the MSPS. To remove these inclusions the MSPS was washed following preparation in an acetone/water series.
  • MSPS size, quantity and quality of the MSPS produced.
  • a range of differently sized MSPS (>500 ⁇ m - ⁇ 150 ⁇ m) were obtained when stir rate, hole bore diameter and extrusion rate were altered. Results indicated that the faster the stir rate of the oil phase, the narrower the bore size of the pierced hole and the higher the extrusion rate, the greater the proportion of smaller diameter MSPS (less than 150 ⁇ m) was produced.
  • Small particles are sought for affinity chromatography as they possess a greater surface area/volume ratio, significantly enhancing their ligand loading capacity and subsequent ability to take up and release macromolecules during chromatography.
  • cross-linked MSPS In order to confer thermal and chemical stability on the MSPS following manufacture, it may be cross-linked with epichlorohydrin under basic conditions using known methods.
  • the cross-linking reaction covalently binds together the polymeric agarose strands by a three-carbon link, instilling a physical rigidity in the particles that reduces the risk of shear damage.
  • Once cross- linked MSPS can be autoclaved (120°C, 15psi, 15 min) without damage or alteration of its physical properties, and is resistant to a whole range of chemical reagents used in further derivatisations.
  • Cross-linked MSPS can be stored quite satisfactorily at room temperature for several months as a suspension in 20% aqueous methanol (to act as an anti-bacterial agent) without any deterioration. No leaching of iron oxide from the agarose matrix was observed.
  • DEAE-, ECTEOLA-, spermine-, TAEA-, EHEP, and HDA-MSPS can all be used for the general isolation of nucleic aids and are listed in decreasing order of affinity for nucleic acids.
  • the degree of ligand loading may be expressed as the ability of a known weight of MSPS to adsorb a known amount of DNA, and the adsorption measured by ultra ⁇ violet spectroscopy. This serves as a method of quality control for the MSPS to check that surface derivatisation had proceeded satifactorily.
  • a suspension of DEAE-MSPS 100 mg ml was incubated with a solution of salmon sperm DNA (50 ⁇ g ml -1 ) at room temperature in an Eppendorf tube. After 30 minutes the MSPS was immobilised with a magnetic concentrator, the supernatant removed and its adsorbance at 260nm and 280nm recorded, and compared with that of the original stock solution of DNA to calculate the level of nucleic acid uptake. Typically, for DEAE-MSPS a figure of at least 95% uptake of salmon sperm DNA was obtained. Similar results were obtained for ECTEOLA-, TAEA- and spermine-MSPS (Table 1).
  • tertiary amines are more basic than secondary or primary amines, solid phase supports derivatised with tertiary amine-containing ligand have a higher positive charge density and therefore a greater affinity for nucleic acids.
  • the adsorbed DNA could be eluted from all samples with at least 80% efficiency (based on A 250 readings) by incubation for up to 30 minutes with 1M NaCl/50mM arginine free base at 65°C.
  • the derivatised MSPS can be stored at 4°C for several months in suspensions of 20% aqueous methanol without any decrease in performance or capacity for nucleic acids.
  • MSPS magnetisable solid phase support
  • the majority of the cleared oil phase is decanted and the aqueous phase containing the beaded MSPS re-washed with deionised water (100ml).
  • the suspension of MSPS is initially sized by sieving through a series of Endecott sieves of mesh size 500 ⁇ m, 250 ⁇ m, 200 ⁇ m, 180 ⁇ m, and 150 ⁇ m using a Fritsch sieve shaker.
  • the fraction containing particles of less than 150 ⁇ m diameter is further sieved with sieves of mesh size lOO ⁇ m, 50 ⁇ m, 32 ⁇ m and 20 ⁇ m.
  • Cross-linked MSPS (0.7 g moist weight) is suspended in 40% sodium hydroxide (3ml) and cooled to 0°C in an ice- water bath. A solution of triethanolamine (0.4ml) in epichlorohydrin (0.7ml) is added drop-wise with occasional shaking, maintaining the temperature at 0°C. After 30 minutes the suspension is allowed to warm 23°C, shaken vigorously using a flask shaker and left to stand for 16 hours. The mixture is then poured into a large volume of 1M hydrochloric acid with stirring, filtered, then washed successively with 1M sodium hydroxide, sterile distilled water, 20% aqueous methanol then finally water. The ECTEOLA-MSPS is stored in 20% aqueous methanol to give a particle density of 100 mg/ml.
  • Cross-linked MSPS (0.5 g moist weight) is suspended in 1M sodium hydroxide (0.4ml). Sodium borohydride (l g) is added followed by diglycidylbutane-1,4-diol (0.5ml). The suspension is shaken at 23°C for 6 hours, then filtered, washed thoroughly with deionised water and immediately resuspended in 5M tris(2-aminoethyl)amine (l l) and shaken at 30"c for 2 hours. The suspension is 0 washed successively with sterile distilled water, 1M sodium chloride, sterile distilled water and finally 0.05M phosphate buffer (pH7). The TAEA-MSPS is stored in 20% aqueous methanol to a final particle density of 100 mg/ml. 5
  • MSPS (2g moist weight) is activated with oxirane groups as described for TAEA-MSPS, then suspended in 5M
  • Cross-linked MSPS (0.9 g moist weight) is suspended in 3040% sodium hydroxide (4ml) and cooled to 0°C in an ice- water bath.
  • the mixture is then poured into a large volume of 1M hydrochloric acid with stirring, filtered, then washed successively with 1M sodium hydroxide, sterile distilled water, 20% aqueous methanol and finally sterile distilled water.
  • the EHEP-MSPS is stored in 20% aqueous methanol to give a final particle density of 100 mg/ml.
  • nucleic acids to be adsorbed by the MSPS can be in a variety of forms, including aqueous solutions of one, or more than one, species of nucleic acid, or semi-crude cell lysate mixtures. Nucleic acids are adsorbed non- specifically by the MSPS at ambient temperature (23°C) from solution at pH7 or below. Nucleic acids can be eluted specifically in pure form from the MSPS by treatment with elution solutions of differing ionic strengths.
  • RNA and DNA can be adsorbed simultaneously by the DEAE-derivatised beads, the RNA eluted using 0.lMNaCl/50mM arginine (free base) at 65°C for 30 minutes.
  • Plasmid DNA can be adsorbed by the MSPS from a cell lysis mixture (boiling lysis) which has been treated with RNAse. Any remaining small fragments of oligoribonucleotide which co-adsorb with the plasmid DNA can be eluted using 0.1M/50mM arginine (free base), then the pure plasmid DNA can be eluted using 1.0M/50mM arginine (free base) at 65°C for 15 minutes.
  • RNA could be adsorbed to and eluted from the DEAE- MSPS, but elution occurred at much lower ionic concentrations and temperatures and at a significantly faster rate.
  • DEAE-MSPS was incubated with a solution of total RNA (50 ⁇ g ml "1 ) at 23°C for 30 minutes, magnetically immobilised and the supernatant removed. Comparison of the A 2 go values of the supernatant and original stock solution of RNA showed that, on average, 90 % of the RNA had been adsorbed by the MSPS.
  • the RNA could be eluted with an efficiency of 80-85% at salt concentrations of 0.1M NaCl up to 1.0M NaCl (50mM arginine free base) at 23°C.
  • DEAE-MSPS can also be used for differentiating plasmid DNA and total cellular RNA.
  • a solution of plasmid pUC 18 was prepared by standard boiling lysis, which contained amounts of RNA carried over from the lysis step.
  • DEAE-MSPS was incubated with this solution under the same conditions used for other protocols, magnetically immobilised, then treated with 0.1M NaCl, to remove adsorbed oligoribonucleotides, then the plasmid DNA eluted using 1.0M/50mM arginine free base. Eluted samples were analysed by agarose gel electrophoresi ⁇ , which showed firstly that the MSPS will adsorb and release plasmid DNA satisfactorily using the standard uptake and elution protocol, and secondly, that RNA was eluted at 0.05M-0.1 NaCl, whilst the plasmid DNA was eluted at a salt concentration of 1.0M NaCl. Therefore, DEAE-MSPS can be used to separate unwanted RNA resulting from cell lysis from plasmid DNA, and provide plasmid DNA of a purity and quality suitable for further applications.
  • DEAE-MSPS appears to selectively release them according to size upon application of elution solutions.
  • the DEAE-MSPS was non-specific in its uptake of a mixtures of nucleic acids from solution, but by application of different concentrations of an elution solution, DNA and RNA could be eluted specifically from the DEAE-MSPS, a procedure which can be scaled down to a microtitre plate format without loss of efficiency.
  • plasmid DNA and RNA could be speciated on the DEAE-MSPS.
  • Total RNA can be isolated from a mixture of RNA and DNA using a method similar to that described above. 250 ⁇ l of a suspension of DEAE-MSPS (100 mg ml -1 ) is aliquotted into an Eppendorf tube and washed twice with sterile distilled water. The nucleic acid solution containing RNA and DNA (up to 50 ⁇ g total) is added to the MSPS and the suspension mixed by end-over-end rotation for 30 minutes at 23°C. The MSPS is magnetically immobilised and the supernatant removed, then 1ml of an elution solution (0.1M NaCl, 50mM arginine free base) is added.
  • an elution solution 0.1M NaCl, 50mM arginine free base
  • 1.5 ml of cell culture is spun in a microcentrifuge for 20 seconds in an Eppendorf tube.
  • the supernatant is aspirated and the cell pellet resuspended in 350 ⁇ l STET buffer (0.1M NaCl, lOmM Tris-HCl pH 8, l EDTA, 5% triton X-100) containing 2 ⁇ l of RNAse A solution (lOmg ml "1 ).
  • 25 ⁇ l of a freshly prepared solution of lysozyme (lOmg ml "1 ) is added in lOmM tris-HCl, pH8.
  • the solution is placed in a boiling water bath for 40 seconds, then spun in a centrifuge at 13,000 rpm for 10 minutes.
  • the pelleted cell debris is removed using a disposable pipette tip, and the lysate solution added to 25mg of DEAE-MSPS (250 ⁇ l of 100 mg ml "1 suspension) in an Eppendorf tube.
  • the suspension is mixed by end-over- end rotation for 30 minutes at 23°C, the MSPS magnetically immobilised and the supernatant removed.
  • the DEAE-MSPS is washed twice with sterile distilled water, and then washed two times with O.lmM NaCl/50mM arginine free base to remove any oligoribonucleotides present in the lysis mixture which may become adsorbed to the MSPS.

Abstract

Biomolecules are separated using magnetisable polymer-based particles derivatised with a ligand having direct binding affinity for nucleic acids or other types of biopolymer molecule. The particles are used for nucleic acid (and other biomolecular) purification and speciations, including double or single stranded nucleic acids, genomic DNA, plasmid DNA, and cellular RNA.

Description

MAGNETIC SOLID PHASE SUPPORTS
This invention relates to the isolation and purification of molecules of biological interest eg proteins, nucleic acids, and other biopolymers.
The purification of molecules of the above kinds often involve multi-step procedures requiring much time, technically complex equipment and potentially hazardous reagents. An affinity chromatography step is often the final or penultimate step. Ideally this step should be employed as early as possible in the process to maximise the yield of desired product and minimise the time required to generate it. Usually this is not feasible as the substance of interest (ligate) is present in a medium not readily amenable to conventional column affinity chromatography. Often the ligate may be present in a mixture of substances containing particulate and/or semi-solid or colloidal material such as cell debris and denatured cell components and/or in a mixture which is highly viscous. Column chromatography demands that both these factors be as low as possible and the steps in a purification procedure prior to affinity chromatography are engaged in minimising these two factors. They also result in the loss of at least some of the desired end product and an increase in the time required to collect it.
The present invention is concerned with the development of relatively simple techniques for use with complex mixtures of high viscosity and/or those containing particulate matter and which are based on the use of magnetisable solid phase support (MSPS) materials. The use of magnetic separation in biological systems has been proposed in recent years. However, in spite of the fact that the facilities required for magnetic separation are much less costly and complex than those required for column chromatography or centrifugation the techniques have not so far received the attention they deserve.
The present invention comprises magnetisable polymer based particles derivatised with ligands possessing direct-binding affinities for nucleic acids and other types of biomolecule, and the use of these particles for nucleic acid (and other biomolecular) purification and speciation, including double or single stranded nucleic acids, genomic DNA, plasmid DNA, and cellular RNA.
The direct binding of the ligand to the target molecule is important to achieve the benefits of this invention as contrasted with prior proposals based on indirect linking of the target molecules eg. through intercalating agents as described in EP 301,899 A.
The present invention comprises particulate support material having magnetic properties and bearing a ligand which binds to molecules of a specific type. From another aspect the present invention comprises a method of separating biomolecules of various types by binding such molecules to ligands which are selective therefore and which are attached to magnetisable particulate support materials. The invention is further apparent from the appended claims.
The magnetic susceptibility of MSPS materials in accordance with the present invention is a function of the weight and size of the particulate material and the quantity of paramagnetic material incorporated therein. This property may therefore be adjusted as desired in order to provide an appropriate selection parameter. In practice a product range of MSPS materials may be manufactured in order to cater for the wide range of separations encountered in both analytical and preparative procedures.
The MSPS materials in accordance with this invention are preferably gels and are conveniently in the form of beads. Such gels may be stabilised by crosslinking eg with epichlorohydrin, leading to greater particle stability especially at high temperatures. Many polymers may be used for the purposes of this invention including cellulose, dextran, polyacrylamide and the synthetic material trisacryl. One of the most preferred materials is agarose. The positive benefits of this polymer are gel strength and biological inertness. The abundance of hydroxyl groups possessed by the agarose matrix allows for easy covalent attachment of various ligands desirable for molecular biology applications and its non-covalent secondary structure also engenders structural stability, porosity and ease of shaping into spheres. Since many molecular biology methodologies are performed at temperatures above that at which agarose melts it would also be desirable to introduce thermal stability into the agarose solid phase support.
MSPS materials consist of at least two separate components a non-magnetisable component which may be chemically derivatised with suitable ligands and a magnetisable component or core. Paramagnetic properties can be introduced into the solid phase support by addition of powdered paramagnetic iron oxide (Fe304) to the agarose during the preparation of the MSPS, which leads to entrapment of the paramagnetic component within the solid phase matrix and gives the particles their magnetisability. MSPS particles should be within a size range which allows the greatest particle surface area exposure to ligate, but at the same time allows the best particle magnetic sedimentation rate. A relationship exists between spherical particle volume and sedimentation rate controlled by the equation F = (^ - ^0) VH (dH/dX) where F = net force X-^ and xv° = the volume susceptibilities, and V = the volume of the particle and H = applied magnetic field and dH/dX + the magnetic field gradient. The magnetisable component should also have a high degree of magnetisable susceptibility to optimise magnetic sedimentation rates.
The ideal magnetisable component can be selected on the basis of the above equation, but in practice relatively few paramagnetic molecules have been used in MSPS. Iron oxide, barium ferrite and nickel oxide may be used.
Iron oxide has many advantages over other substances for
MSPS construction since it possesses a high magnetic susceptibility, is readily available, inexpensive and non toxic. A highly preferred system for our purposes entails iron oxide as the magnetisable component for
MSPS and agarose as the polymer matrix in which to embed it. However, other natural and synthetic polymers may be used as MSPS matrix material including cellulose, alginate, dextran and perfluorocarbon based supports.
MSPS may be prepared either by encapsulation of the magnetisable component during the preparation of the particle, or by addition of the magnetisable component subsequent to particle formation.
Encapsulation
Encapsulation of the magnetisable component is convenient when iron oxide is used in MSPS construction. The magnetisable component can be mixed in an aqueous suspension of cellulose or agarose and allowed to cure, the water is removed and the dried material ground to the size range required.
Alternatively, MSPS may be prepared by spraying or droplet formation and this leads to beaded particles. MSPS may be prepared by addition of a suspension of sodium alginate and iron oxide dropped into a solution of calcium chloride. Droplet formation can be brought about through emulsification techniques and thee have been employed for the formation of spherical magnetisable dextran, albumin, acrylates, acrolein and polyglutaraldehyde. In this system an aqueous emulsion of the matrix polymer and magnetisable component is prepared. This is added to mineral oil and the two phase system stirred. A precipitate is formed of beaded particles.
Subsequent addition
Preparation of MSPS by addition of the magnetisable component after particle formation has been achieved with derivatised and underivatised sepharose. It has been reported that coating sepharose particles with a suspension of ferrite in water or hydrocarbon solvent results in their magnetisability without significant loss of activity of the derivatised form.
As an alternative to this method the particle is coated with an aqueous solution of polyacrylamide containing ferric oxide. The resulting particles tend to be large >250 μ and very porous. However, they are amenable to activation via either the polysaccharide or polyacrylamide component. Preparation of MSPS
In one method we have used to prepare agarose MSPS an aqueous suspension is extruded into an immiscible organic phase. A suspension of paramagnetic iron oxide, Fe304, (4% w/v) in molten agarose (2% w/v) was extruded into vegetable oil stirred with an overhead paddle stirrer using a specially adapted plastic syringe. The end of the syringe was sealed, then drilled with a small hole to allow the molten agarose/iron oxide mixture to be extruded into the oil phase. The MSPS was collected, washed with water and sized by sieving, then checked under a light microscope set up for Kόhler illumination for morphological homogeneity. The particles formed were highly bead like and uniformly spherical, a consequence of both the extrusion technique and the immiscibility of the oil and water.
The highly spherical nature of the particles produced is particularly desirable because it prevents local concentration change effects that might occur with particles whose surface is more heterogeneous. It is particularly important to maintain uniform ionic concentrations around the surface of a particle in order that local absorption and/or desorption does not occur and alter the bulk properties of the support.
When the MSPS was viewed under the light microscope, small yellow inclusions were observed incorporated within the agarose matrix which were believed to be vegetable oil retained in the matrix of the agarose during the preparation of the MSPS. To remove these inclusions the MSPS was washed following preparation in an acetone/water series.
Many factors determine the size, quantity and quality of the MSPS produced. A range of differently sized MSPS (>500μm - <150μm) were obtained when stir rate, hole bore diameter and extrusion rate were altered. Results indicated that the faster the stir rate of the oil phase, the narrower the bore size of the pierced hole and the higher the extrusion rate, the greater the proportion of smaller diameter MSPS (less than 150μm) was produced. Small particles are sought for affinity chromatography as they possess a greater surface area/volume ratio, significantly enhancing their ligand loading capacity and subsequent ability to take up and release macromolecules during chromatography.
In an illustrative preparation, 10 ml of molten agarose/iron oxide suspension was extruded from a 10ml syringe at a constant extrusion rate of 3.3 ml sec"1 (10ml extruded over a period of 3 sec) into vegetable oil stirred at _6000 rpm. The effect of bore size diameter on MSPS production was studied first, with holes of 0.7, 0.5, 0.3 and 0.1mm being drilled in the sealed end of the syringe. A diameter of 0.7mm gave the largest amount of MSPS greater than 500μm diameter, whilst negligible amounts of the smaller sized particles (less than 150μm diameter) were formed. Using syringes drilled with 0.5mm and 0.3mm diameter holes gave a slight increase of these smaller sized MSPS, but large amounts of the particles greater than 500μm were still produced. Only when a syringe with a hole bore size of 0.1mm was used was there a significant increase in the proportion of smaller diameter MSPS produced.
The effect of different extrusion rate on MSPS production, has also been investigated using a syringe of drilled hole bore of 0.1mm and stir rate of 6000rpm. The greater the extrusion rate, the greater the proportion of smaller diameter MSPS collected, and a rate of 3.3 ml sec" (rate measured as above) gave the best results. Similarly, we have found that increasing the stir rate leads to an increase in the amount of smaller sized (less than 150μm diameter) MSPS produced.
Taken together, the above results indicate that the conditions which favour production of smaller MSPS are those of small hole bore size, high extrusion rate and stir rate. Although the size range distribution of the agarose MSPS produced is wide, sufficient amounts of small particles can be produced for derivatisation and applications. It was observed that 20μm appeared to be the minimum diameter of MSPS attainable using this production method, any material recovered below this size generally consisted of non-spherical lumps and waste material of varying iron oxide/agarose content.
In order to confer thermal and chemical stability on the MSPS following manufacture, it may be cross-linked with epichlorohydrin under basic conditions using known methods. The cross-linking reaction covalently binds together the polymeric agarose strands by a three-carbon link, instilling a physical rigidity in the particles that reduces the risk of shear damage. Once cross- linked MSPS can be autoclaved (120°C, 15psi, 15 min) without damage or alteration of its physical properties, and is resistant to a whole range of chemical reagents used in further derivatisations. Cross-linked MSPS can be stored quite satisfactorily at room temperature for several months as a suspension in 20% aqueous methanol (to act as an anti-bacterial agent) without any deterioration. No leaching of iron oxide from the agarose matrix was observed. Surface derivatisation of MSPS with affinity liσands
Many procedures already exist for the derivatisation of cellulose, dextran and agarose with affinity ligands, and these can be utilised with a minimum of adaption for our agarose MSPS.
We have prepared several MSPS derivatives for nucleic acid purification. These are listed below; the type of surface ligand is given along with its abbreviated form: (i) Diethylaminoethyl - DEAE
(ii) Epichlorohydrin/triethanolamine - ECTEOLA (iii) Spermine
(iv) Diglycidylbutane-1,4,-diol/Tris(aminoethyl) amino - TAEA (v) Epichlorohydrin/hydroxyethylpiperazine
EHEP (vi) Diglycidylbutane-1,4,-diol/Hexane-1,6- diamino - HDA
DEAE-, ECTEOLA-, spermine-, TAEA-, EHEP, and HDA-MSPS can all be used for the general isolation of nucleic aids and are listed in decreasing order of affinity for nucleic acids. The degree of ligand loading may be expressed as the ability of a known weight of MSPS to adsorb a known amount of DNA, and the adsorption measured by ultra¬ violet spectroscopy. This serves as a method of quality control for the MSPS to check that surface derivatisation had proceeded satifactorily. In an illustrative procedure, a suspension of DEAE-MSPS (100 mg ml ) was incubated with a solution of salmon sperm DNA (50μg ml-1) at room temperature in an Eppendorf tube. After 30 minutes the MSPS was immobilised with a magnetic concentrator, the supernatant removed and its adsorbance at 260nm and 280nm recorded, and compared with that of the original stock solution of DNA to calculate the level of nucleic acid uptake. Typically, for DEAE-MSPS a figure of at least 95% uptake of salmon sperm DNA was obtained. Similar results were obtained for ECTEOLA-, TAEA- and spermine-MSPS (Table 1).
The nitrogen atoms of the ligand become protonated in solution, generating a positively charged MSPS to which the negatively charged phosphate backbone of the nucleic acid is attracted (Fig. 1). Since tertiary amines are more basic than secondary or primary amines, solid phase supports derivatised with tertiary amine-containing ligand have a higher positive charge density and therefore a greater affinity for nucleic acids. This has been confirmed in so far as the DEAE, ECTEOLA and TAEA supports performed best in the DNA uptake assay, whilst the EHEP, and HDA-MSPS showed decreasing affinity for DNA , not because of a low degree of surface ligand coverage (the amounts of reagents used were sufficient to ensure high surface derivatization) , but because of the lower affinity of the secondary and primary amine ligands for DNA. The spermine-MSPS displayed good affinity for DNA possibly because its long chain polyamine nature enables it to bind DNA molecules by wrapping around them and that the ionic charge of attraction of the multi-protonated polyamines is greater.
The adsorbed DNA could be eluted from all samples with at least 80% efficiency (based on A250 readings) by incubation for up to 30 minutes with 1M NaCl/50mM arginine free base at 65°C. The derivatised MSPS can be stored at 4°C for several months in suspensions of 20% aqueous methanol without any decrease in performance or capacity for nucleic acids. EXAMPLE 1 Preparation of beaded magnetic aσarose
Two methods for the preparation of magnetisable solid phase support (MSPS) are given below.
(i) A solution of molten agarose (2% w/v) containing paramagnetic iron oxide, Fe304 (4% w/v), and sodium azide (0.02% w/v) is extruded at a rate of 3.3 ml s"1 from a 0.1 mm diameter hole drilled at the end of a sealed 10ml syringe into vegetable oil (100ml), rapidly stirred by an overhead paddle stirrer at 6000 rpm. Stirring is continued for 1 minute after extrusion is complete then 100ml of deionised water is added and the two-phase mixture left to stand on a slab magnet for 16 hours. The majority of the cleared oil phase is decanted and the aqueous phase containing the beaded MSPS re-washed with deionised water (100ml). The suspension of MSPS is initially sized by sieving through a series of Endecott sieves of mesh size 500μm, 250μm, 200μm, 180μm, and 150μm using a Fritsch sieve shaker. The fraction containing particles of less than 150μm diameter is further sieved with sieves of mesh size lOOμm, 50μm, 32μm and 20μm. All fractions collected are then washed successively with 30:70 v/v acetone:water, 70:30 v/v acetone:water then 100% anhydrous acetone, and the MSPS is stored in 20% aqueous methanol to act as an anti-bacterial agent.
(ii) The procedure of (1) is followed except that homogenisation is used instead of overhead stirring. The initial solution is extruded into vegetable oil stirred at 11,000 rpm in a homogeniser. Homogenisation is continued for a further 1 minute after extrusion is complete then 100 ml of deionised water is added and the two-phase mixture left to stand on a slab magnet for 16 hours. The remaining procedure is as described in (1) . Particles of diameter 20-50μm or 50-100μm are selected for further derivatization with affinity ligands and biological applications, and the greatest proportion of these sizes is produced using the homogeniser method.
5
Thermal stability is introduced into the MSPS prepared as described above by crosslinking agarose polymers using epichlorohydrin. Two methods have been used:
101- 10ml of settled volume of MSPS is stirred with 100ml 0.05 M NaOH and 1ml epichlorohydrin using a rotary shaker at room temperature for 3 h. Subsequently, the MSPS is washed several times with 0.05M NaOH.
!52. 10 ml of settled volume MSPS is stirred with
100 ml 0.05 M NaOH, 1 ml epichlorohydrin and 0.05g NaBH4 using a rotary shaker for 2 h at 60°c. Subsequently, the MSPS is washed several times with warm distilled water.
20
EXAMPLE 2 Preparation of derivatised MSPS
(i DEAE
25 Cross-linked MSPS (3.2 g moist weight) is suspended in 10% sodium hydroxide (15ml) and cooled to 0°C in an ice- water bath. A solution of 2-(N-N -diethylamino)ethyl chloride hydrochloride (3g) in water (4ml) is added slowly to the suspension with occasional shaking. The
30 suspension is left at 0°C for 30 minutes, then allowed to warm 23°C. After 16 hours, the DEAE-MSPS is washed successively with 2M sodium chloride, sterile distilled water, 30:70 v/v ethanol:water then 70:30 v/v ethanol:water, and finally suspended in 20% aqueous 5 methanol to give a final particle density of 100 mg/ml. ( ii ) ECTEOLA
Cross-linked MSPS (0.7 g moist weight) is suspended in 40% sodium hydroxide (3ml) and cooled to 0°C in an ice- water bath. A solution of triethanolamine (0.4ml) in epichlorohydrin (0.7ml) is added drop-wise with occasional shaking, maintaining the temperature at 0°C. After 30 minutes the suspension is allowed to warm 23°C, shaken vigorously using a flask shaker and left to stand for 16 hours. The mixture is then poured into a large volume of 1M hydrochloric acid with stirring, filtered, then washed successively with 1M sodium hydroxide, sterile distilled water, 20% aqueous methanol then finally water. The ECTEOLA-MSPS is stored in 20% aqueous methanol to give a particle density of 100 mg/ml.
(iii) Spermine
Cross-linked MSPS (0.5 g moist weight) is washed successively with 30:70 v/v dioxane:water, 70:30 v/v dioxane:water, anhydrous dioxane and finally suspended in anhydrous dioxane (1ml). 1,1-carbonyldiimidazole (O.lg) is added under a nitrogen atmosphere and the suspension shaken for 30 minutes at 23°C. The MSPS is washed again with anhydrous dioxane, the cooled to 0°C. A solution of spermine (0.56g) in deionised water (2.5ml) is slowly added with agitation, and the suspension of MSPS left at 4°C for 16 hours. It is then shaken for a further 2 hours at 23°C, then washed successively with sterile distilled water, 1M hydrochloric acid and finally sterile distilled water. The spermine-MSPS is stored in 20% aqueous methanol to a final particle density of 100 mg/ml. ( IV ) TAEA
Cross-linked MSPS (0.5 g moist weight) is suspended in 1M sodium hydroxide (0.4ml). Sodium borohydride (l g) is added followed by diglycidylbutane-1,4-diol (0.5ml). The suspension is shaken at 23°C for 6 hours, then filtered, washed thoroughly with deionised water and immediately resuspended in 5M tris(2-aminoethyl)amine (l l) and shaken at 30"c for 2 hours. The suspension is 0 washed successively with sterile distilled water, 1M sodium chloride, sterile distilled water and finally 0.05M phosphate buffer (pH7). The TAEA-MSPS is stored in 20% aqueous methanol to a final particle density of 100 mg/ml. 5
(v) HDA
MSPS (2.5g moist weight) is activated with oxirane groups as described for TAEA-MSPS, then suspended in 5M
20 hexane-l,6-diamine (ml). The suspension is shaken at 30°C for 2 hours, then filtered, washed successively with sterile distilled water, 1M sodium chloride, sterile distilled water and finally 0.05M phosphate buffer (pH7). The HDA-MSPS is stored in 20% aqueous
25 methanol to give a final particle density of 100 mg/ml.
(vi) EHEP
Cross-linked MSPS (0.9 g moist weight) is suspended in 3040% sodium hydroxide (4ml) and cooled to 0°C in an ice- water bath. A solution of N-(2-hydroxyethyl)piperazine (0.5ml) in epichlorohydrin (0.9ml) is added drop-wise with occasional shaking, maintaining the temperature at 0°C. After 30 minutes the suspension is allowed to 35 warm to 23°C, then shaken vigorously using a flask shaker and left to stand for 16 hours. The mixture is then poured into a large volume of 1M hydrochloric acid with stirring, filtered, then washed successively with 1M sodium hydroxide, sterile distilled water, 20% aqueous methanol and finally sterile distilled water. The EHEP-MSPS is stored in 20% aqueous methanol to give a final particle density of 100 mg/ml.
Specific protocols for the separation and purification of different types of nucleic acids are given below.
Three specific protocols for the separation and purification of different types of nucleic acids have been developed:
(i) DNA isolation
(ii) Isolation of total RNA from nucleic acid mixtures (iii) Isolation of plasmid DNA from a cell lysate mixture. The nucleic acids to be adsorbed by the MSPS can be in a variety of forms, including aqueous solutions of one, or more than one, species of nucleic acid, or semi-crude cell lysate mixtures. Nucleic acids are adsorbed non- specifically by the MSPS at ambient temperature (23°C) from solution at pH7 or below. Nucleic acids can be eluted specifically in pure form from the MSPS by treatment with elution solutions of differing ionic strengths.
A mixture of RNA and DNA can be adsorbed simultaneously by the DEAE-derivatised beads, the RNA eluted using 0.lMNaCl/50mM arginine (free base) at 65°C for 30 minutes.
Plasmid DNA can be adsorbed by the MSPS from a cell lysis mixture (boiling lysis) which has been treated with RNAse. Any remaining small fragments of oligoribonucleotide which co-adsorb with the plasmid DNA can be eluted using 0.1M/50mM arginine (free base), then the pure plasmid DNA can be eluted using 1.0M/50mM arginine (free base) at 65°C for 15 minutes.
Total RNA could be adsorbed to and eluted from the DEAE- MSPS, but elution occurred at much lower ionic concentrations and temperatures and at a significantly faster rate. DEAE-MSPS was incubated with a solution of total RNA (50μg ml"1) at 23°C for 30 minutes, magnetically immobilised and the supernatant removed. Comparison of the A2go values of the supernatant and original stock solution of RNA showed that, on average, 90 % of the RNA had been adsorbed by the MSPS. The RNA could be eluted with an efficiency of 80-85% at salt concentrations of 0.1M NaCl up to 1.0M NaCl (50mM arginine free base) at 23°C.
studies on the effect of elution solution composition on salmon sperm DNA elution showed that below 0.3M NaCl, negligible amounts of DNA were eluted, even at 65°C. Above 0.3M NaCl, DNA began to be eluted from the MSPS, and full elution was achieved at 1.0M NaCl/50mM arginine free base/65°C. The rate of DNA elution was much slower than that for RNA: samples of DEAE-MSPS which had adsorbed salmon sperm DNA were treated for 1, 5, 15 and 30 minute periods with elution solutions of 0.1, 0.5 and 1.0M NaCl (all 50mM arginine) at 65°C. No DNA was washed from the beads at 0.1M NaCl; at 0.5M NaCl, elution occurred but only up to a maximum of 68% of adsorbed DNA. Treating the particles with 1.0M NaCl led to 45% elution of DNA after 1 minute, but the full 30 minute period was still needed to achieve 90% elution (Table 2) . DEAE-MSPS can also be used for differentiating plasmid DNA and total cellular RNA. A solution of plasmid pUC 18 was prepared by standard boiling lysis, which contained amounts of RNA carried over from the lysis step. DEAE-MSPS was incubated with this solution under the same conditions used for other protocols, magnetically immobilised, then treated with 0.1M NaCl, to remove adsorbed oligoribonucleotides, then the plasmid DNA eluted using 1.0M/50mM arginine free base. Eluted samples were analysed by agarose gel electrophoresiε, which showed firstly that the MSPS will adsorb and release plasmid DNA satisfactorily using the standard uptake and elution protocol, and secondly, that RNA was eluted at 0.05M-0.1 NaCl, whilst the plasmid DNA was eluted at a salt concentration of 1.0M NaCl. Therefore, DEAE-MSPS can be used to separate unwanted RNA resulting from cell lysis from plasmid DNA, and provide plasmid DNA of a purity and quality suitable for further applications.
Though exhibiting no preference in its adsorption of nucleic acids, DEAE-MSPS appears to selectively release them according to size upon application of elution solutions. The DEAE-MSPS was non-specific in its uptake of a mixtures of nucleic acids from solution, but by application of different concentrations of an elution solution, DNA and RNA could be eluted specifically from the DEAE-MSPS, a procedure which can be scaled down to a microtitre plate format without loss of efficiency. Similarly, plasmid DNA and RNA could be speciated on the DEAE-MSPS. EXAMPLE 3 DNA isolation
25 mg (250μl of 100 g ml"1 suspension) of DEAE-MSPS is aliquotted into an Eppendorf tube and washed twice with sterile distilled water. A crude cell lysate containing the DNA to be isolated (up to 50μg total) is added to the MSPS and the suspension mixed by end-over-end rotation at 23°C for 30 minutes. The MSPS is magnetically immobilised using a magnetic tube stand/holder and the supernatant removed. 1ml of an elution solution consisting of 1M NaCl/50mM arginine free base is added to the MSPS and the suspension mixed by end-over-end rotation at 65°C for 30 minutes. The MSPS is then magnetically immobilised and the supernatant containing the eluted DNA removed.
EXAMPLE 4
Isolation of total RNA from a nucleic acid mixture
Total RNA can be isolated from a mixture of RNA and DNA using a method similar to that described above. 250μl of a suspension of DEAE-MSPS (100 mg ml-1) is aliquotted into an Eppendorf tube and washed twice with sterile distilled water. The nucleic acid solution containing RNA and DNA (up to 50μg total) is added to the MSPS and the suspension mixed by end-over-end rotation for 30 minutes at 23°C. The MSPS is magnetically immobilised and the supernatant removed, then 1ml of an elution solution (0.1M NaCl, 50mM arginine free base) is added. The suspension mixed by end-over-end rotation for 30 minutes at 65°C, the MSPS magnetically immobilised and the supernatant containing eluted RNA removed. A second elution procedure is then carried out using 1M NaCl/50_ι_M arginine free base to elute DNA which remains adsorbed to the matrix. EXAMPLE 5
Isolation of plasmid DNA from cell lysis mixture
1.5 ml of cell culture is spun in a microcentrifuge for 20 seconds in an Eppendorf tube. The supernatant is aspirated and the cell pellet resuspended in 350μl STET buffer (0.1M NaCl, lOmM Tris-HCl pH 8, l EDTA, 5% triton X-100) containing 2μl of RNAse A solution (lOmg ml"1). 25μl of a freshly prepared solution of lysozyme (lOmg ml"1) is added in lOmM tris-HCl, pH8. The solution is placed in a boiling water bath for 40 seconds, then spun in a centrifuge at 13,000 rpm for 10 minutes. The pelleted cell debris is removed using a disposable pipette tip, and the lysate solution added to 25mg of DEAE-MSPS (250μl of 100 mg ml"1 suspension) in an Eppendorf tube. The suspension is mixed by end-over- end rotation for 30 minutes at 23°C, the MSPS magnetically immobilised and the supernatant removed. The DEAE-MSPS is washed twice with sterile distilled water, and then washed two times with O.lmM NaCl/50mM arginine free base to remove any oligoribonucleotides present in the lysis mixture which may become adsorbed to the MSPS. 1ml of elution solution (0.5M NaCl/50mM arginine free base) is then added and the suspension mixed by end-over-end rotation at 65°C for 15 minutes. The MSPS is magnetically immobilised and the supernatant containng purified plasmid DNA is removed. The DNA can then be precipitated, analysed directly by agarose gel electrophoresis, or manipulated in other ways. TABLE 1
Efficiency of adsorbtion of salmon sperm DNA by differently derivatized MSPS
MSPS Adsorbtion / %
DEAE 95
ECTEOLA 89
TAEA 95
Spermine 86
EHEP 67
HDA 40
25mg of MSPS incubated with 1ml of salmon sperm DNA (50μg ml"1), 30min, 23°C. (Average values of at least three experiments).
TABLE 2
Elution of adsorbed salmon sperm DNA from DEAE-MSPS using different elution solutions
.NaCll Elution / % lmin 5min 15min 30min
0.1 0 0 0 0
0.2 . . . 2
0.3 . . . 25
0.4 . . . 52
0.5 18 44 56 68
0.6 . . . -80
0.7 . . . 78
0.8 . . . 80
0.9 - 88
1.0 45 71 72 97
All elution solutions 50mM arginine free base. Elution for 30min, 65°C. 25mg of DEAE-MSPS incubated with 1ml of salmon sperm DNA (50μg ml"1), 30mi__, 23°C. (Average values of at least three experiments).

Claims

1. Magnetisable polymer-based particles derivatised with a ligand having direct binding affinity for nucleic acids or other types of biopolymer molecule.
2. Magnetisable particles according to claim 1, in which the polymer is in gel form.
3. Magnetisable particles according to claim 1 or 2, in which the polymer is cross-linked.
4. Magnetisable particles according to claim 2, or 3, in which the particles are beads.
5. Magnetisable particles according to any of claims 1 to 4 in which the polymer is agarose.
6. Magnetisable particles according to any of claims 1 to 5, in which the ligand is one capable of assuming a positive charge at pH7 or below and of reversibly binding directly to a negatively charged group or moiety in the target molecule.
7. Magnetisable particles according to any of claims 1 to 6, in which the ligand comprises a primary, secondary, or tertiary amine group.
8. Magnetisable particles according to claim 7, in which the ligand is selected from
(i) Diethylaminoethyl - DEAE
(ii) Epichlorohydrin/triethanola ine - ECTEOLA
(iii) Spermine
(iv) Diglycidylbutane-1,4,-diol/Tris(aminoethyl) amino - TAEA (v) Epichlorohydrin/hydroxyethylpiperazine
- EHEP (vi) Diglycidylbutane-1,4,-diol/Hexane-1,6- diamino - HDA 5
9. Magnetisable particles according to any of the preceding claims, in which the magnetisable component comprises magnetic iron oxide.
10 10. Magnetisable particles according to any of the preceding claims having a particle size range of 20-150 μ .
11. Magnetisable particles according to any of the 15 preceding claims, prepared by extrusion of an aqueous solution of the derivatised polymer containing suspended particles of a magnetisable material into a water- immiscible oil phase.
20 12. A method of preparing magnetisable particles according to any of the preceding claims, which comprises extruding a suspension of magnetisable particles in an aqueous solution of the derivatised polymer through an orifice into a continuously stirred
25 water-immiscible oil phase.
13. A method according to claim 12, in which the orifice has a bore of 0.1 - 0.3 mms.
30 14. A method according to claim 12 or 13, in which the extrusion ratio is 2.0 - 3.0 ml/sec.
15. A method according to claim 12, 13 or 14, in which the oil phase is stirred with a rotary stirrer at 4000- 35 6000 revolutions/min.
16. A method according to claims 12, 13 or 14 in which the oil phase is stirred by a homogeniser.
17. A method of separating biomolecules using 5 magnetisable particles according to any of claims 1 to
11.
18. A method according to claim 17, for separating nucleic acids, from other biomolecules.
10
19. A method according to claim 17, for separating DNA or RNA from mixtures thereof or from other cell components.
15 20. A method according to claim 17, for separating plasmid DNA.
21. A method according to claim 18, 19, 20 in which the target substance is adsorbed on the magnetisable 20 particles at pH 7 or below and eluted selectively with elution solutions of approprate ionic strength.
25
0
5
PCT/GB1993/002289 1992-11-06 1993-11-05 Magnetic solid phase supports WO1994011103A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP93924712A EP0621802A1 (en) 1992-11-06 1993-11-05 Magnetic solid phase supports
AU54273/94A AU5427394A (en) 1992-11-06 1993-11-05 Magnetic solid phase supports

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929223334A GB9223334D0 (en) 1992-11-06 1992-11-06 Magnetic solid phase supports
GB9223334.5 1992-11-06

Publications (1)

Publication Number Publication Date
WO1994011103A1 true WO1994011103A1 (en) 1994-05-26

Family

ID=10724683

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1993/002289 WO1994011103A1 (en) 1992-11-06 1993-11-05 Magnetic solid phase supports

Country Status (4)

Country Link
EP (1) EP0621802A1 (en)
AU (1) AU5427394A (en)
GB (1) GB9223334D0 (en)
WO (1) WO1994011103A1 (en)

Cited By (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2287662A (en) * 1993-12-23 1995-09-27 Pall Corp Affinity separation method
WO1996003653A1 (en) * 1994-07-27 1996-02-08 Silica Gel Ges.Mbh Absorptionstechnik, Apparatebau Superparamagnetic particles, process for their production and their use
EP0757106A2 (en) * 1995-07-07 1997-02-05 Toyo Boseki Kabushiki Kaisha Nucleic acid-bondable magnetic carrier and method for isolating nucleic acid using the same
WO1999015023A2 (en) * 1997-09-22 1999-04-01 Kiwi Co-Operative Dairies Limited Recovery process
WO2000020114A1 (en) * 1998-10-06 2000-04-13 Bioprocessing Ltd. Adsorbent medium and its use in purifying dna
WO2001071354A2 (en) * 2000-03-20 2001-09-27 Massachusetts Institute Of Technology Inorganic particle conjugates
EP1260595A2 (en) * 1995-07-07 2002-11-27 Toyo Boseki Kabushiki Kaisha Nucleic acid-bondable magnetic carrier and method for isolating nucleic acid using the same
WO2003004151A1 (en) * 2001-07-04 2003-01-16 Qiagen As Preparation of polymer particles
WO2006017428A2 (en) * 2004-08-03 2006-02-16 Becton, Dickinson And Company Use of magnetic material to direct isolation of compounds and fractionation of multipart samples
US20060166233A1 (en) * 2004-05-03 2006-07-27 Handylab, Inc. Method and apparatus for processing polynucleotide-containing samples
US7183002B2 (en) 2000-03-24 2007-02-27 Qiagen, Gmbh Porous ferro- or ferrimagnetic glass particles for isolating molecules
JP2007516425A (en) * 2003-05-13 2007-06-21 アイシス ファーマシューティカルズ インコーポレイティッド Rapid purification of nucleic acids by solution capture for later analysis using mass spectrometry
US7956175B2 (en) 2003-09-11 2011-06-07 Ibis Biosciences, Inc. Compositions for use in identification of bacteria
US8097416B2 (en) 2003-09-11 2012-01-17 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US8101234B2 (en) 1997-11-13 2012-01-24 Massachusetts Institute Of Technology Highly luminescent color-selective nanocrystalline materials
US8158354B2 (en) 2003-05-13 2012-04-17 Ibis Biosciences, Inc. Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US20120197009A1 (en) * 1997-12-06 2012-08-02 Life Technologies Corporation Isolation of nucleic acids
US8546082B2 (en) 2003-09-11 2013-10-01 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US20140011201A1 (en) * 2003-05-13 2014-01-09 Ibis Biosciences, Inc. Method for the purification of targeted nucleic acids from background nucleic acids
US8691969B2 (en) 1994-12-12 2014-04-08 Life Technologies As Isolation of nucleic acid
US8883490B2 (en) 2006-03-24 2014-11-11 Handylab, Inc. Fluorescence detector for microfluidic diagnostic system
US8895311B1 (en) 2001-03-28 2014-11-25 Handylab, Inc. Methods and systems for control of general purpose microfluidic devices
US8894947B2 (en) 2001-03-28 2014-11-25 Handylab, Inc. Systems and methods for thermal actuation of microfluidic devices
US9028773B2 (en) 2001-09-12 2015-05-12 Handylab, Inc. Microfluidic devices having a reduced number of input and output connections
US9040288B2 (en) 2006-03-24 2015-05-26 Handylab, Inc. Integrated system for processing microfluidic samples, and method of using the same
US9051604B2 (en) 2001-02-14 2015-06-09 Handylab, Inc. Heat-reduction methods and systems related to microfluidic devices
US9080207B2 (en) 2006-03-24 2015-07-14 Handylab, Inc. Microfluidic system for amplifying and detecting polynucleotides in parallel
USD742027S1 (en) 2011-09-30 2015-10-27 Becton, Dickinson And Company Single piece reagent holder
US9186677B2 (en) 2007-07-13 2015-11-17 Handylab, Inc. Integrated apparatus for performing nucleic acid extraction and diagnostic testing on multiple biological samples
US9217143B2 (en) 2007-07-13 2015-12-22 Handylab, Inc. Polynucleotide capture materials, and methods of using same
US9222954B2 (en) 2011-09-30 2015-12-29 Becton, Dickinson And Company Unitized reagent strip
US9238223B2 (en) 2007-07-13 2016-01-19 Handylab, Inc. Microfluidic cartridge
US9259734B2 (en) 2007-07-13 2016-02-16 Handylab, Inc. Integrated apparatus for performing nucleic acid extraction and diagnostic testing on multiple biological samples
US9259735B2 (en) 2001-03-28 2016-02-16 Handylab, Inc. Methods and systems for control of microfluidic devices
US9347586B2 (en) 2007-07-13 2016-05-24 Handylab, Inc. Automated pipetting apparatus having a combined liquid pump and pipette head system
US9530928B2 (en) 1997-11-25 2016-12-27 The Regents Of The University Of California Semiconductor nanocrystal probes for biological applications and process for making and using such probes
US9618139B2 (en) 2007-07-13 2017-04-11 Handylab, Inc. Integrated heater and magnetic separator
USD787087S1 (en) 2008-07-14 2017-05-16 Handylab, Inc. Housing
US9670528B2 (en) 2003-07-31 2017-06-06 Handylab, Inc. Processing particle-containing samples
US9765389B2 (en) 2011-04-15 2017-09-19 Becton, Dickinson And Company Scanning real-time microfluidic thermocycler and methods for synchronized thermocycling and scanning optical detection
US9815057B2 (en) 2006-11-14 2017-11-14 Handylab, Inc. Microfluidic cartridge and method of making same
US10179910B2 (en) 2007-07-13 2019-01-15 Handylab, Inc. Rack for sample tubes and reagent holders
US10822644B2 (en) 2012-02-03 2020-11-03 Becton, Dickinson And Company External files for distribution of molecular diagnostic tests and determination of compatibility between tests
US10900066B2 (en) 2006-03-24 2021-01-26 Handylab, Inc. Microfluidic system for amplifying and detecting polynucleotides in parallel
US11453906B2 (en) 2011-11-04 2022-09-27 Handylab, Inc. Multiplexed diagnostic detection apparatus and methods
US11806718B2 (en) 2006-03-24 2023-11-07 Handylab, Inc. Fluorescence detector for microfluidic diagnostic system
US11959126B2 (en) 2021-10-07 2024-04-16 Handylab, Inc. Microfluidic system for amplifying and detecting polynucleotides in parallel

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4335094A (en) * 1979-01-26 1982-06-15 Mosbach Klaus H Magnetic polymer particles
WO1983003426A1 (en) * 1982-03-29 1983-10-13 SCHRÖDER, Ulf Magnetic carbohydrate particles as carriers for affinity separation purposes, e.g. cell separation
US4452773A (en) * 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
WO1986003136A1 (en) * 1984-11-28 1986-06-05 University Patents, Inc. Affinity chromatography using dried calcium alginate-magnetite separation media in a magnetically stabilized fluidized bed
EP0184710A2 (en) * 1984-12-08 1986-06-18 Bayer Ag Magnetic microspheres
EP0234083A2 (en) * 1986-02-25 1987-09-02 Tosoh Corporation Carrier for a biologically active component for immunoassay or enzymatic reaction

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4335094A (en) * 1979-01-26 1982-06-15 Mosbach Klaus H Magnetic polymer particles
WO1983003426A1 (en) * 1982-03-29 1983-10-13 SCHRÖDER, Ulf Magnetic carbohydrate particles as carriers for affinity separation purposes, e.g. cell separation
US4452773A (en) * 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
WO1986003136A1 (en) * 1984-11-28 1986-06-05 University Patents, Inc. Affinity chromatography using dried calcium alginate-magnetite separation media in a magnetically stabilized fluidized bed
EP0184710A2 (en) * 1984-12-08 1986-06-18 Bayer Ag Magnetic microspheres
EP0234083A2 (en) * 1986-02-25 1987-09-02 Tosoh Corporation Carrier for a biologically active component for immunoassay or enzymatic reaction

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0621802A1 *

Cited By (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567615A (en) * 1993-12-23 1996-10-22 Pall Corporation Affinity separation method
GB2287662A (en) * 1993-12-23 1995-09-27 Pall Corp Affinity separation method
GB2287662B (en) * 1993-12-23 1997-11-19 Pall Corp Affinity separation method
US5928958A (en) * 1994-07-27 1999-07-27 Pilgrimm; Herbert Superparamagnetic particles, process for their manufacture and usage
WO1996003653A1 (en) * 1994-07-27 1996-02-08 Silica Gel Ges.Mbh Absorptionstechnik, Apparatebau Superparamagnetic particles, process for their production and their use
US6274121B1 (en) 1994-07-27 2001-08-14 Herbert Pilgrimm Superparamagnetic particles, process for their manufacture and use
US8691969B2 (en) 1994-12-12 2014-04-08 Life Technologies As Isolation of nucleic acid
EP1260595A3 (en) * 1995-07-07 2002-12-18 Toyo Boseki Kabushiki Kaisha Nucleic acid-bondable magnetic carrier and method for isolating nucleic acid using the same
EP1260595A2 (en) * 1995-07-07 2002-11-27 Toyo Boseki Kabushiki Kaisha Nucleic acid-bondable magnetic carrier and method for isolating nucleic acid using the same
US5945525A (en) * 1995-07-07 1999-08-31 Toyo Boseki Kabushiki Kaisha Method for isolating nucleic acids using silica-coated magnetic particles
EP0757106A2 (en) * 1995-07-07 1997-02-05 Toyo Boseki Kabushiki Kaisha Nucleic acid-bondable magnetic carrier and method for isolating nucleic acid using the same
US7119194B2 (en) 1995-07-07 2006-10-10 Toyo Boseki Kabushiki Kaisha Nucleic acid-bondable magnetic carrier and method for isolating nucleic acid using the same
EP0757106A3 (en) * 1995-07-07 1997-05-21 Toyo Boseki Nucleic acid-bondable magnetic carrier and method for isolating nucleic acid using the same
WO1999015023A2 (en) * 1997-09-22 1999-04-01 Kiwi Co-Operative Dairies Limited Recovery process
WO1999015023A3 (en) * 1997-09-22 1999-06-17 Kiwi Co Operative Dairies Limi Recovery process
US8481112B2 (en) 1997-11-13 2013-07-09 Massachusetts Institute Of Technology Highly luminescent color-selective nanocrystalline materials
US8481113B2 (en) 1997-11-13 2013-07-09 Massachusetts Institute Of Technology Highly luminescent color-selective nanocrystalline materials
US8158193B2 (en) 1997-11-13 2012-04-17 Massachusetts Institute Of Technology Highly luminescent color-selective nanocrystalline materials
US8101234B2 (en) 1997-11-13 2012-01-24 Massachusetts Institute Of Technology Highly luminescent color-selective nanocrystalline materials
US9530928B2 (en) 1997-11-25 2016-12-27 The Regents Of The University Of California Semiconductor nanocrystal probes for biological applications and process for making and using such probes
US20120197009A1 (en) * 1997-12-06 2012-08-02 Life Technologies Corporation Isolation of nucleic acids
US6723539B1 (en) 1998-10-06 2004-04-20 Bioprocessing, Ltd. Absorbent medium containing particles of chopped cellulose or agarose sponge material having functional groups
WO2000020114A1 (en) * 1998-10-06 2000-04-13 Bioprocessing Ltd. Adsorbent medium and its use in purifying dna
US8192646B2 (en) 2000-03-20 2012-06-05 Massachusetts Institute Of Technology Inorganic particle conjugates
WO2001071354A2 (en) * 2000-03-20 2001-09-27 Massachusetts Institute Of Technology Inorganic particle conjugates
US7470379B2 (en) 2000-03-20 2008-12-30 Massachusetts Institute Of Technology Inorganic particle conjugates
US6921496B2 (en) 2000-03-20 2005-07-26 Massachusetts Institute Of Technology Inorganic particle conjugates
WO2001071354A3 (en) * 2000-03-20 2002-08-01 Massachusetts Inst Technology Inorganic particle conjugates
US8034259B2 (en) 2000-03-20 2011-10-11 Massachusetts Institute Of Technology Inorganic particle conjugates
US7183002B2 (en) 2000-03-24 2007-02-27 Qiagen, Gmbh Porous ferro- or ferrimagnetic glass particles for isolating molecules
US7922917B2 (en) 2000-03-24 2011-04-12 Qiagen Gmbh Porous ferro- or ferrimagnetic glass particles for isolating molecules
US8202427B2 (en) 2000-03-24 2012-06-19 Qiagen Gmbh Porous ferro-or ferrimagnetic glass particles for isolating molecules
US9051604B2 (en) 2001-02-14 2015-06-09 Handylab, Inc. Heat-reduction methods and systems related to microfluidic devices
US9528142B2 (en) 2001-02-14 2016-12-27 Handylab, Inc. Heat-reduction methods and systems related to microfluidic devices
US9677121B2 (en) 2001-03-28 2017-06-13 Handylab, Inc. Systems and methods for thermal actuation of microfluidic devices
US10571935B2 (en) 2001-03-28 2020-02-25 Handylab, Inc. Methods and systems for control of general purpose microfluidic devices
US10619191B2 (en) 2001-03-28 2020-04-14 Handylab, Inc. Systems and methods for thermal actuation of microfluidic devices
US10351901B2 (en) 2001-03-28 2019-07-16 Handylab, Inc. Systems and methods for thermal actuation of microfluidic devices
US8894947B2 (en) 2001-03-28 2014-11-25 Handylab, Inc. Systems and methods for thermal actuation of microfluidic devices
US9259735B2 (en) 2001-03-28 2016-02-16 Handylab, Inc. Methods and systems for control of microfluidic devices
US8895311B1 (en) 2001-03-28 2014-11-25 Handylab, Inc. Methods and systems for control of general purpose microfluidic devices
WO2003004151A1 (en) * 2001-07-04 2003-01-16 Qiagen As Preparation of polymer particles
US7785660B2 (en) 2001-07-04 2010-08-31 Qiagen Gmbh Preparation of polymer particles
US9028773B2 (en) 2001-09-12 2015-05-12 Handylab, Inc. Microfluidic devices having a reduced number of input and output connections
JP2007516425A (en) * 2003-05-13 2007-06-21 アイシス ファーマシューティカルズ インコーポレイティッド Rapid purification of nucleic acids by solution capture for later analysis using mass spectrometry
US8476415B2 (en) 2003-05-13 2013-07-02 Ibis Biosciences, Inc. Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
JP2012132924A (en) * 2003-05-13 2012-07-12 Ibis Biosciences Inc Method for rapidly purifying nucleic acid by solution capture for subsequent analysis by mass spectrometry
US20140011201A1 (en) * 2003-05-13 2014-01-09 Ibis Biosciences, Inc. Method for the purification of targeted nucleic acids from background nucleic acids
US8158354B2 (en) 2003-05-13 2012-04-17 Ibis Biosciences, Inc. Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US7964343B2 (en) * 2003-05-13 2011-06-21 Ibis Biosciences, Inc. Method for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US11078523B2 (en) 2003-07-31 2021-08-03 Handylab, Inc. Processing particle-containing samples
US10865437B2 (en) 2003-07-31 2020-12-15 Handylab, Inc. Processing particle-containing samples
US9670528B2 (en) 2003-07-31 2017-06-06 Handylab, Inc. Processing particle-containing samples
US10731201B2 (en) 2003-07-31 2020-08-04 Handylab, Inc. Processing particle-containing samples
US8546082B2 (en) 2003-09-11 2013-10-01 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US7956175B2 (en) 2003-09-11 2011-06-07 Ibis Biosciences, Inc. Compositions for use in identification of bacteria
US8013142B2 (en) 2003-09-11 2011-09-06 Ibis Biosciences, Inc. Compositions for use in identification of bacteria
US8097416B2 (en) 2003-09-11 2012-01-17 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US10364456B2 (en) 2004-05-03 2019-07-30 Handylab, Inc. Method for processing polynucleotide-containing samples
US20060166233A1 (en) * 2004-05-03 2006-07-27 Handylab, Inc. Method and apparatus for processing polynucleotide-containing samples
US10604788B2 (en) 2004-05-03 2020-03-31 Handylab, Inc. System for processing polynucleotide-containing samples
US11441171B2 (en) 2004-05-03 2022-09-13 Handylab, Inc. Method for processing polynucleotide-containing samples
US10443088B1 (en) 2004-05-03 2019-10-15 Handylab, Inc. Method for processing polynucleotide-containing samples
US8852862B2 (en) * 2004-05-03 2014-10-07 Handylab, Inc. Method for processing polynucleotide-containing samples
US10494663B1 (en) 2004-05-03 2019-12-03 Handylab, Inc. Method for processing polynucleotide-containing samples
WO2006017428A3 (en) * 2004-08-03 2006-10-26 Becton Dickinson Co Use of magnetic material to direct isolation of compounds and fractionation of multipart samples
WO2006017428A2 (en) * 2004-08-03 2006-02-16 Becton, Dickinson And Company Use of magnetic material to direct isolation of compounds and fractionation of multipart samples
AU2005271688B2 (en) * 2004-08-03 2011-10-06 Becton, Dickinson And Company Use of magnetic material to direct isolation of compounds and fractionation of multipart samples
US11141734B2 (en) 2006-03-24 2021-10-12 Handylab, Inc. Fluorescence detector for microfluidic diagnostic system
US10900066B2 (en) 2006-03-24 2021-01-26 Handylab, Inc. Microfluidic system for amplifying and detecting polynucleotides in parallel
US10857535B2 (en) 2006-03-24 2020-12-08 Handylab, Inc. Integrated system for processing microfluidic samples, and method of using same
US9802199B2 (en) 2006-03-24 2017-10-31 Handylab, Inc. Fluorescence detector for microfluidic diagnostic system
US10843188B2 (en) 2006-03-24 2020-11-24 Handylab, Inc. Integrated system for processing microfluidic samples, and method of using the same
US10821436B2 (en) 2006-03-24 2020-11-03 Handylab, Inc. Integrated system for processing microfluidic samples, and method of using the same
US10821446B1 (en) 2006-03-24 2020-11-03 Handylab, Inc. Fluorescence detector for microfluidic diagnostic system
US10799862B2 (en) 2006-03-24 2020-10-13 Handylab, Inc. Integrated system for processing microfluidic samples, and method of using same
US10913061B2 (en) 2006-03-24 2021-02-09 Handylab, Inc. Integrated system for processing microfluidic samples, and method of using the same
US11085069B2 (en) 2006-03-24 2021-08-10 Handylab, Inc. Microfluidic system for amplifying and detecting polynucleotides in parallel
US10695764B2 (en) 2006-03-24 2020-06-30 Handylab, Inc. Fluorescence detector for microfluidic diagnostic system
US8883490B2 (en) 2006-03-24 2014-11-11 Handylab, Inc. Fluorescence detector for microfluidic diagnostic system
US11142785B2 (en) 2006-03-24 2021-10-12 Handylab, Inc. Microfluidic system for amplifying and detecting polynucleotides in parallel
US11666903B2 (en) 2006-03-24 2023-06-06 Handylab, Inc. Integrated system for processing microfluidic samples, and method of using same
US11806718B2 (en) 2006-03-24 2023-11-07 Handylab, Inc. Fluorescence detector for microfluidic diagnostic system
US9080207B2 (en) 2006-03-24 2015-07-14 Handylab, Inc. Microfluidic system for amplifying and detecting polynucleotides in parallel
US9040288B2 (en) 2006-03-24 2015-05-26 Handylab, Inc. Integrated system for processing microfluidic samples, and method of using the same
US10710069B2 (en) 2006-11-14 2020-07-14 Handylab, Inc. Microfluidic valve and method of making same
US9815057B2 (en) 2006-11-14 2017-11-14 Handylab, Inc. Microfluidic cartridge and method of making same
US11466263B2 (en) 2007-07-13 2022-10-11 Handylab, Inc. Diagnostic apparatus to extract nucleic acids including a magnetic assembly and a heater assembly
US10632466B1 (en) 2007-07-13 2020-04-28 Handylab, Inc. Integrated apparatus for performing nucleic acid extraction and diagnostic testing on multiple biological samples
US10071376B2 (en) 2007-07-13 2018-09-11 Handylab, Inc. Integrated apparatus for performing nucleic acid extraction and diagnostic testing on multiple biological samples
US10625261B2 (en) 2007-07-13 2020-04-21 Handylab, Inc. Integrated apparatus for performing nucleic acid extraction and diagnostic testing on multiple biological samples
US10065185B2 (en) 2007-07-13 2018-09-04 Handylab, Inc. Microfluidic cartridge
US10139012B2 (en) 2007-07-13 2018-11-27 Handylab, Inc. Integrated heater and magnetic separator
US11845081B2 (en) 2007-07-13 2023-12-19 Handylab, Inc. Integrated apparatus for performing nucleic acid extraction and diagnostic testing on multiple biological samples
US10844368B2 (en) 2007-07-13 2020-11-24 Handylab, Inc. Diagnostic apparatus to extract nucleic acids including a magnetic assembly and a heater assembly
US10100302B2 (en) 2007-07-13 2018-10-16 Handylab, Inc. Polynucleotide capture materials, and methods of using same
US9186677B2 (en) 2007-07-13 2015-11-17 Handylab, Inc. Integrated apparatus for performing nucleic acid extraction and diagnostic testing on multiple biological samples
US11549959B2 (en) 2007-07-13 2023-01-10 Handylab, Inc. Automated pipetting apparatus having a combined liquid pump and pipette head system
US9238223B2 (en) 2007-07-13 2016-01-19 Handylab, Inc. Microfluidic cartridge
US10625262B2 (en) 2007-07-13 2020-04-21 Handylab, Inc. Integrated apparatus for performing nucleic acid extraction and diagnostic testing on multiple biological samples
US10179910B2 (en) 2007-07-13 2019-01-15 Handylab, Inc. Rack for sample tubes and reagent holders
US10717085B2 (en) 2007-07-13 2020-07-21 Handylab, Inc. Integrated apparatus for performing nucleic acid extraction and diagnostic testing on multiple biological samples
US10234474B2 (en) 2007-07-13 2019-03-19 Handylab, Inc. Automated pipetting apparatus having a combined liquid pump and pipette head system
US9217143B2 (en) 2007-07-13 2015-12-22 Handylab, Inc. Polynucleotide capture materials, and methods of using same
US10590410B2 (en) 2007-07-13 2020-03-17 Handylab, Inc. Polynucleotide capture materials, and methods of using same
US11266987B2 (en) 2007-07-13 2022-03-08 Handylab, Inc. Microfluidic cartridge
US10875022B2 (en) 2007-07-13 2020-12-29 Handylab, Inc. Integrated apparatus for performing nucleic acid extraction and diagnostic testing on multiple biological samples
US9618139B2 (en) 2007-07-13 2017-04-11 Handylab, Inc. Integrated heater and magnetic separator
US11254927B2 (en) 2007-07-13 2022-02-22 Handylab, Inc. Polynucleotide capture materials, and systems using same
US11060082B2 (en) 2007-07-13 2021-07-13 Handy Lab, Inc. Polynucleotide capture materials, and systems using same
US9347586B2 (en) 2007-07-13 2016-05-24 Handylab, Inc. Automated pipetting apparatus having a combined liquid pump and pipette head system
US9259734B2 (en) 2007-07-13 2016-02-16 Handylab, Inc. Integrated apparatus for performing nucleic acid extraction and diagnostic testing on multiple biological samples
USD787087S1 (en) 2008-07-14 2017-05-16 Handylab, Inc. Housing
US9765389B2 (en) 2011-04-15 2017-09-19 Becton, Dickinson And Company Scanning real-time microfluidic thermocycler and methods for synchronized thermocycling and scanning optical detection
US10781482B2 (en) 2011-04-15 2020-09-22 Becton, Dickinson And Company Scanning real-time microfluidic thermocycler and methods for synchronized thermocycling and scanning optical detection
US11788127B2 (en) 2011-04-15 2023-10-17 Becton, Dickinson And Company Scanning real-time microfluidic thermocycler and methods for synchronized thermocycling and scanning optical detection
US9222954B2 (en) 2011-09-30 2015-12-29 Becton, Dickinson And Company Unitized reagent strip
US9480983B2 (en) 2011-09-30 2016-11-01 Becton, Dickinson And Company Unitized reagent strip
USD905269S1 (en) 2011-09-30 2020-12-15 Becton, Dickinson And Company Single piece reagent holder
US10076754B2 (en) 2011-09-30 2018-09-18 Becton, Dickinson And Company Unitized reagent strip
USD742027S1 (en) 2011-09-30 2015-10-27 Becton, Dickinson And Company Single piece reagent holder
USD831843S1 (en) 2011-09-30 2018-10-23 Becton, Dickinson And Company Single piece reagent holder
US11453906B2 (en) 2011-11-04 2022-09-27 Handylab, Inc. Multiplexed diagnostic detection apparatus and methods
US10822644B2 (en) 2012-02-03 2020-11-03 Becton, Dickinson And Company External files for distribution of molecular diagnostic tests and determination of compatibility between tests
US11959126B2 (en) 2021-10-07 2024-04-16 Handylab, Inc. Microfluidic system for amplifying and detecting polynucleotides in parallel

Also Published As

Publication number Publication date
AU5427394A (en) 1994-06-08
EP0621802A1 (en) 1994-11-02
GB9223334D0 (en) 1992-12-23

Similar Documents

Publication Publication Date Title
WO1994011103A1 (en) Magnetic solid phase supports
US6783962B1 (en) Particulate material for purification of bio-macromolecules
US4675113A (en) Affinity chromatography using dried calcium alginate-magnetite separation media in a magnetically stabilized fluidized bed
DE60012318T2 (en) pH DEPENDENT IONTAUSCHERMATRIX AND METHOD OF USE IN THE INSULATION OF NUCLEIC ACIDS
EP1694420B1 (en) Method for the concentration and purification of biological compounds
US5610274A (en) Production and use of magnetic porous inorganic materials
DE69923960T2 (en) Small dense microporous solid support materials, their preparation and their use for the purification of large macromolecules and bioparticles
Li et al. Efficient on‐chip proteolysis system based on functionalized magnetic silica microspheres
JP6452704B2 (en) Production of magnetic particles
JP2005532799A (en) Binding of target substance
JP2009118858A (en) Cell concentration and lysate clearance using paramagnetic particles
KR19990035924A (en) Magnetic polymer particles based on polyvinyl alcohol, methods of making and uses thereof
JP2022515769A (en) Large pore size agarose
Vergara-Barberan et al. Recent advances in aptamer-based miniaturized extraction approaches in food analysis
Tanyolaç et al. A new low cost magnetic material: magnetic polyvinylbutyral microbeads
DE60033505T2 (en) PARTICLE MATERIAL FOR SPINE CLEANING OF BIOMAKROLEOLS, SUCH AS PLASMID DNA, CHROMOSOME DNA, RNA, VIRAL DNA, BACTERIA AND VIRUSES
JP2003524680A (en) Affinity control type material using stimulus-responsive polymer and separation / purification method using the material
JP4198461B2 (en) Lysate clearance and nucleic acid isolation using silane-treated silica substrates
EP0434354B1 (en) Separation material for blood coagulation factor, preparation and use thereof
US5167812A (en) Affinity chromatogry using dried calcium alginate-magnetite separation media in a magnetically stabilized fluidized bed
US5167811A (en) Affinity chromatography using dried calcium alginate-magnetite separation media in a magnetically stabilized fluidized bed
DE10053553C2 (en) Device for the detection and enrichment of biomolecules
WO2020069385A1 (en) Isolation of dna and rna from a single sample
Hashemi-Moghaddam Role of magnetic polymer–coated nanoparticles in separation sciences
Şenel et al. DNA adsorption on a poly‐l‐lysine‐immobilized poly (2‐hydroxyethyl methacrylate) membrane

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA GB JP RU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1993924712

Country of ref document: EP

ENP Entry into the national phase

Ref country code: US

Ref document number: 1994 256315

Date of ref document: 19940706

Kind code of ref document: A

Format of ref document f/p: F

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 1993924712

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1993924712

Country of ref document: EP